IDEXX Laboratories, Inc. (IDXX)
NASDAQ: IDXX · Real-Time Price · USD
713.56
+1.09 (0.15%)
At close: Nov 12, 2025, 4:00 PM EST
714.39
+0.83 (0.12%)
After-hours: Nov 12, 2025, 5:13 PM EST
IDEXX Laboratories Stock Forecast
Stock Price Forecast
The 9 analysts that cover IDEXX Laboratories stock have a consensus rating of "Buy" and an average price target of $683.89, which forecasts a -4.16% decrease in the stock price over the next year. The lowest target is $475 and the highest is $830.
Price Target: $683.89 (-4.16%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for IDEXX Laboratories stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 1 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 7 | 7 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $765 → $805 | Buy | Maintains | $765 → $805 | +12.81% | Nov 4, 2025 |
| UBS | UBS | Hold Maintains $710 → $750 | Hold | Maintains | $710 → $750 | +5.11% | Nov 4, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $675 → $775 | Buy | Maintains | $675 → $775 | +8.61% | Nov 4, 2025 |
| BTIG | BTIG | Strong Buy Maintains $785 → $830 | Strong Buy | Maintains | $785 → $830 | +16.32% | Nov 4, 2025 |
| Stifel | Stifel | Hold → Strong Buy Upgrades $640 → $700 | Hold → Strong Buy | Upgrades | $640 → $700 | -1.90% | Oct 31, 2025 |
Financial Forecast
Revenue This Year
4.32B
from 3.90B
Increased by 10.76%
Revenue Next Year
4.67B
from 4.32B
Increased by 8.22%
EPS This Year
12.87
from 10.67
Increased by 20.58%
EPS Next Year
14.45
from 12.87
Increased by 12.29%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.5B | 4.9B | |||
| Avg | 4.3B | 4.7B | |||
| Low | 4.1B | 4.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 14.8% | 12.8% | |||
| Avg | 10.8% | 8.2% | |||
| Low | 5.5% | 2.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 13.53 | 15.29 | |||
| Avg | 12.87 | 14.45 | |||
| Low | 12.07 | 13.49 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 26.8% | 18.8% | |||
| Avg | 20.6% | 12.3% | |||
| Low | 13.2% | 4.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.